KW-6356
NootropicsPhase 2b (program discontinued)Also known as: KW6356
KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Adenosine A2A receptors are concentrated in the basal ganglia, where they oppose dopamine signaling, so blocking them is a non-dopaminergic way to support motor function.
Overview
At A Glance
KW-6356 binds adenosine A2A receptors as a high-affinity antagonist and inverse agonist, reducing both adenosine-stimulated and constitutive A2A signaling in striatal output pathways. By relieving A2A-mediated inhibition of dopaminergic motor circuits it improves motor output wit…
Overview
KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Adenosine A2A receptors are concentrated in the basal ganglia, where they oppose dopamine signaling, so blocking them is a non-dopaminergic way to support motor function. It is a structurally distinct successor to istradefylline (Nourianz).
Chemical Information
IUPAC Name
Not yet available
CAS Number
858979-50-7
Molecular Formula
Not yet available
Molecular Mass
397.4 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join other researchers already signed up
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join other researchers already signed up
Interactions
Contraindications
Investigational compound with no clinical-use guidance. Avoid in pregnancy/breastfeeding.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$109.99
—
1
1
capsule
Tracking since Jul 1, 2026 · 1 data point
Vendors Selling KW-6356
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
View Full Dosage Guide →
Protocols, calculator & safety for KW-6356
Related Articles
All PostsResearch Score
0 PubMed results
Quality Indicators
Data Completeness
63%Quick Facts
Molecular Weight
397.4 g/mol
Administration
Oral
CAS Number
858979-50-7
Trial Phase
Phase 2b (program discontinued)
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is KW-6356 used for in research?
KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Adenosine A2A receptors are concentrated in the basal ganglia, where they oppose dopamine signaling, so blocking them is a non-dopaminergic way to support motor function. It is a structurally distinct successor to istradefylline (Nourianz).
What forms does KW-6356 come in?
KW-6356 is available in capsule form.
How much does KW-6356 cost?
Prices start at $109.99 across 1 vendor.
How do I compare KW-6356 vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Research Benches
Reference pages that put KW-6356 next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Free 2026 Peptide Cheat Sheet (PDF)
Reconstitution math, concentration charts, half-lives, and vendor links. The reference we wish we had on day one.
